Physician profile
Mark A Davis
NPI 1457465916
$10,873.71
in general payments reported to CMS, 2019-2025
45 companies · $794 in 2025
The $794 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $2,204 · 2021: $2,121 · 2022: $1,473 · 2023: $1,320 · 2024: $831 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,603.21 | 2019-2025 | Evenity, Otezla, Prolia |
| Astrazeneca Pharmaceuticals Lp | $1,211.27 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $983.25 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $851.09 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $527.59 | 2021-2025 | |
| Pfizer INC. | $493.84 | 2019-2025 | |
| Esperion Therapeutics, INC. | $484.98 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $468.08 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $422.05 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.18 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $368.32 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Abbott Laboratories | $309.80 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Jot Dx |
| Abbvie INC. | $270.35 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $258.41 | 2020-2022 | |
| Amarin Pharma, INC. | $211.10 | 2019-2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $188.67 | 2020-2025 | Injectafer |
| Corcept Therapeutics | $185.16 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $176.18 | 2022-2025 | Gvoke Hypopen |
| Smith+Nephew, INC. | $149.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $136.25 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $131.80 | 2019-2021 | |
| Organogenesis INC. | $125.00 | 2019 | |
| Glaxosmithkline, LLC. | $99.71 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $93.95 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $84.74 | 2020-2021 | |
| Astellas Pharma US INC | $62.09 | 2023-2024 | Veozah |
| Abiomed | $53.64 | 2024 | Impella |
| Phathom Pharmaceuticals, INC. | $51.09 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $47.84 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.15 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $42.09 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $40.77 | 2022-2023 | Onpattro |
| Ironwood Pharmaceuticals, INC | $36.64 | 2019-2020 | |
| Dexcom, INC. | $31.96 | 2021-2024 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $28.53 | 2025 | |
| Eisai INC. | $28.25 | 2021 | |
| Lundbeck LLC | $27.04 | 2025 | Rexulti |
| Inari Medical, INC. | $26.49 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cvrx, INC. | $24.26 | 2025 | Barostim Neo System |
| Inspire Medical Systems, INC. | $22.14 | 2023 | Inspire |
| Otsuka America Pharmaceutical, INC. | $19.34 | 2023 | Rexulti |
| Mylan Specialty L.P. | $17.56 | 2019 | |
| Bioxcel Therapeutics, INC. | $16.70 | 2023 | Igalmi |
| Irhythm Technologies, INC. | $16.30 | 2024 | Zio Xt Patch, Zio Monitor |
| Sanofi Pasteur INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.